focus -WSS

focus

author：focus 2025-09-27 12:55:59 - browse：1

Amylyx founders — Justin Klee (left) and Joshua Cohen are the co-founders and co-CEOs of Amylyx Pharmaceuticals. Kayana Szymczak for STAT

Amylyx Pharmaceuticals said Friday that its treatment for ALS, called Relyvrio, failed to provide any benefit for patients in a large clinical trial — a stunning outcome that now has the company considering a voluntary withdrawal of the approved medicine from the market.

“This is really hard for us, and it’s really hard for our team who care so much, but it’s so much harder for people with ALS and their families, and we have to keep that perspective,” said a somber Justin Klee, Amylyx’s co-founder and co-CEO, in an interview with STAT on Thursday evening.

In the Phase 3 study involving 664 people with ALS, Relyvrio failed to outperform a placebo on an ALS functional rating scale that measures the ability to perform daily living tasks, walk, breathe, speak, and swallow. The company did not provide detailed results for the study’s primary goal, but said the calculation for statistical significance was 0.67 — well above the 0.05 threshold for success and an indication that Relyvrio provided no benefit at all.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： The new shift in health care is toward less care

hotspot

entertainment

WSS

A new study sees potential in DNA sequencing of infants

Victims of gun violence feel impacts long after bullet wound

Beach reads and more: STAT's 2023 summer book list

Why 40% Americans with Parkinson’s don’t see a neurologist

Iowa House, Senate pass 6

Sanofi CEO defends move to abandon profit guidance, boost research

hotspot

focus

knowledge

BioMarin wins approval for gene therapy to treat hemophilia A

Living with Fabry disease, a condition that causes chronic pain

Continuity nursing helped my family in our darkest PICU moments

Ambulance rides for just $100? Advisers want major billing fixes

Walensky prepares to leave CDC — and Congress — behind

HPV cancer vaccine study demonstrates efficacy

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Medicare solvency divides Republicans at the presidential debate

Duchenne breakthrough therapy leaves behind pioneering families

Study: New antibiotic targets gonorrhea as well as last existing drug

knowledge

It's time to get medical device identifiers over the finish line

Study: Pain burden is higher in Black NFL players than white ones

Palantir health business leans on meeting customers’ needs

More doctors should go into startup world

Lecanemab for Alzheimer's is coming. Is the health system ready?

Excited delirium, Elijah McClain, and emergency physicians

hotspot

hotspot

entertainment

knowledge